Chiltern Acquisitions Contribute to 44% Revenue Increase

Friday, July 17, 2009 09:06 AM

Chiltern International reported a 44% revenue increase for the year ended March 31, 2009, due in large part to acquisitions. The UK-based CRO attributed 15% of its growth to acquisitions, including the recent acquisition of Brazil CRO Vigiun.

Chiltern's revenues were 73.7 million pounds ($120.9 million), compared with 51.2 million pounds for year ended March 31, 2008. The CRO's operating profit was 244,000 pounds ($400K), compared with a loss of 1.1 million pounds in 2008.

Commenting on the results, Chiltern CEO Glenn Kerkhof said,"We are growing significantly faster than the sector average ... We continue to develop and deepen our experience and expertise in each of our business units and expand our geographic network. We look forward to another year of progress despite the difficult market conditions."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs